VFMCRP announces U.S. Court upholds validity of Velphoro® patent
14.9.2022 16:05:00 EEST | Business Wire | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the U.S. District Court for the District of Delaware issued a judgment in VFMCRP’s favor regarding U.S. patent no. 9,561,251 which covers the formulation for Velphoro® (sucroferric oxyhydroxide). The decision, subject to appeal, holds that the generic sucroferric oxyhydroxide product proposed by Teva Pharmaceuticals USA, Inc., in its Abbreviated New Drug Application (ANDA) will infringe the Velphoro® U.S. patent no. 9,561,251, which expires in July 2030 (including pediatric extension). Currently, Velphoro® is protected by multiple Orange Book listed patents which expire between May 2029 and May 2035.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220821005007/en/
A further ANDA patent infringement lawsuit against Teva based on patents no. 10,682,376, no. 10,695,367 and no 11,013,761, all expiring in May 2029 remains pending.
“CSL Vifor welcomes the decision by the U.S. District Court to uphold the patent validity of Velphoro® which highlights the innovation and strength of our intellectual property,” said Florian Jehle, Chief Executive Officer of VFMCRP. “We are vigorously defending our intellectual property and protecting our market position. With this decision, we can continue to deliver this innovative drug to improve the lives of patients with chronic kidney disease on dialysis.”
VFMCRP has previously settled disputes with Lupin Pharmaceuticals, Inc and Annora Pharma Pvt. Ltd. which had filed ANDAs to market a generic version of Velphoro®. These ANDA filers will be able to launch a generic version of Velphoro® in the United States on an agreed-upon date. Details of all settlements are confidential.
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.
About Velphoro®
Velphoro® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with chronic kidney disease on dialysis. Velphoro® has been launched in 32 countries at the end of 2021, with more than 100,000 patients estimated to use the drug on a yearly basis.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220821005007/en/
Contact information
CSL Vifor Media Contact
Thomas Hutter
Mobile: +41 79 957 96 73
Email: media@viforpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era19.10.2026 12:00:00 EEST | Press release
Boomi, the data activation company for AI, today announced it has acquired Elementary Data, a provider of the widely adopted data observability solution that powers every workflow and AI agent with reliable data. Following Lunar.dev, Elementary is Boomi’s latest acquisition, strengthening the Boomi Enterprise Platform with the observability, quality, governance, and discovery capabilities enterprises need to deliver trusted data for AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019376249/en/ Boomi Acquires Elementary Data to Bring Trusted, Governed Data to the AI Era Key Takeaways What Boomi acquired. Elementary provides unified observability, quality, governance, and discovery. Founded in 2022, Elementary began as an open-source project — now adopted by 1,500+ data teams, with 1.1M + monthly downloads, and a ~4,000-member community. In 2024, it launched Elementary Cloud which added enterprise-grade capabilities on t
Reply Earns “NVIDIA Physical AI Specialization” for Production-Ready Robotics and Digital Twins19.10.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY] is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. The specialization was awarded following a technical assessment covering a customer implementation, solution architecture, certified OpenUSD expertise and Reply’s development roadmap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019881053/en/ Reply is among the first NVIDIA partners in the world to achieve the “Physical AI Specialization” within the NVIDIA Partner Network (NPN), in recognition of its expertise in developing and deploying AI-driven robotics and digital twin solutions for real-world operating environments. Physical AI is becoming increasingly relevant in manufacturing, warehousing and logistics as companies mo
Sagemcom Unveils Its New-Generation of VSB (Video Soundbox), Now Bringing Home Cinema and Karaoke to Every Living Room, First Deployed by DNA in Finland19.10.2026 11:00:00 EEST | Press release
Sagemcom announces the immediate availability of the new generation of VSB (Video Soundbox). Since its launch, operators around the world have chosen Video Soundbox to offer their customers a 4K set-top box and speakers combined in a single device. Building on this success, Sagemcom introduces its new VSB that takes home entertainment one step further. It is the world’s first set-top box for operators based on Broadcom’s BCM74116 SoC to be deployed. The VSB now offers deeper bass and wider sound spatialization for an even more immersive experience. Thanks to audio designed by Bang & Olufsen and Dolby Atmos, the sound is pure, powerful and multidimensional for all types of content. Dolby Vision brings true colors and sharp pictures. Today, the VSB goes far beyond the traditional TV experience. It can be further enhanced with Wireless Surround Speakers. Available as an option, they extend the sound across the entire room: films and series take on a true cinema dimension, while live sport
EchoMark Launches European Operations and Partner Ecosystem19.10.2026 11:00:00 EEST | Press release
EchoMark, the award winning invisible forensic watermarking company that identifies the source of information leaks, often in minutes, today announced the launch of its European operations. The full EchoMark platform is now available with European Union data residency, giving customers the option to run watermarking, administration, and leak investigations entirely on EU-based infrastructure. EchoMark has also entered into a partnership with Nomios, a leading European cybersecurity services provider, to deliver, deploy, and support the platform across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909554797/en/ EchoMark is also investing in the wider European insider risk community. The company has joined the Insider Risk Practitioner Alliance (IRPA) as a Secretariat Tier 2 Partner and is a Gold sponsor of the UK Insider Risk Management Collaboration Centre and the Nordic Insider Risk Management Centre of Exce
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 202619.10.2026 01:05:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that it will present new data from its oncology portfolio during the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data being presented at ESMO further reinforce our confidence in these novel investigational approaches and their potential to improve and prolong the lives of patients with difficult-to-treat gastrointestinal cancers,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “Importantly, these findings not only provide new clinical insights, but they also inform our registrational development programs, including the Phase 3 KRAS G12D and TGFβR2×PD-1 studies already underway.” Details on rapid oral presentations at ESMO include: INCB161734 (KRAS G12D) Safety and Efficacy of Oral KRAS G12D Inhibitor INCB161734 as Monotherapy or in Combination with Cetuximab (Cetux) in Patients (pts) with Advanced/Metastatic Colorectal Cancer (CRC) Session:
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom